Search Result

Results for "

diabetic neuropathic pain

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (1) Adenosine Kinase (1) Adrenergic Receptor (2) Aminopeptidase (1) Arrestin (2) Calcium Channel (1) CGRP Receptor (1) EGFR (1) Environmental Pollutants (1) ERK (2) GABA Receptor (2) GPR84 (1) iGluR (2) Isotope-Labeled Compounds (1) Neprilysin (1) Neurotensin Receptor (2) Opioid Receptor (1) Potassium Channel (1) Reference Standards (1) Serotonin Transporter (2) Sodium Channel (2) α-synuclein (2)
By Research Areas:	Cancer (2) Infection (2) Inflammation/Immunology (4) Metabolic Disease (5) Neurological Disease (17)

By Targets:

5-HT Receptor (1)

Adenosine Kinase (1)

Adrenergic Receptor (2)

Aminopeptidase (1)

Arrestin (2)

Calcium Channel (1)

CGRP Receptor (1)

EGFR (1)

Environmental Pollutants (1)

ERK (2)

GABA Receptor (2)

GPR84 (1)

iGluR (2)

Isotope-Labeled Compounds (1)

Neprilysin (1)

Neurotensin Receptor (2)

Opioid Receptor (1)

Potassium Channel (1)

Reference Standards (1)

Serotonin Transporter (2)

Sodium Channel (2)

α-synuclein (2)

By Research Areas:

Cancer (2)

Infection (2)

Inflammation/Immunology (4)

Metabolic Disease (5)

Neurological Disease (17)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Art. -Nr.	Produktname	Target	Forschungsgebiete	Chemical Structure

HY-142240

Crisugabalin HSK16149	Calcium Channel	Neurological Disease
Crisugabalin is an orally active, selective ligand for the α2δ subunit of voltage-gated calcium channels, with a target IC₅₀ of 3.96 nM in rats. Crisugabalin inhibits the binding of [ ³H]gabapentin to the α2δ subunit, reduces calcium influx, decreases neuronal excitability, and impairs nociceptive transmission. Crisugabalin alleviates mechanical allodynia, neuropathic pain and inflammatory pain in rats, and reduces phase II pain behaviors. Crisugabalin can be used in research related to chronic pain, neuropathic pain, diabetic neuropathy, fibromyalgia, inflammatory pain, diabetic peripheral neuropathy and postherpetic neuralgia.

HY-Y0790

Cuminaldehyde 1 Publications Verification p-Isopropylbenzaldehyde	Environmental Pollutants α-synuclein	Infection Neurological Disease Inflammation/Immunology Cancer
Cuminaldehyde is the main component of Cuminum cyminum and has multiple biological activities, including anti-inflammatory, anti-cancer, anti-diabetic, anti-injury, anti-neuropathy and antibacterial effects. Cuminaldehyde is an inhibitor of aldose reductase (IC₅₀= 0.00085 mg/mL), α-glucosidase (IC₅₀=0.5 mg/mL) and lipoxygenase (IC₅₀=1370 μM). Cuminaldehyde also inhibits the fibrillation of α-synuclein and prevents its aggregation. Cuminaldehyde has potential application value in the research of neurodegenerative diseases, cancer, diabetes and neuropathic pain diseases .

HY-164795A

SBI-810 hydrochloride	Neurotensin Receptor Arrestin iGluR ERK Sodium Channel	Neurological Disease
SBI-810 hydrochloride is a blood-brain barrier-permeable NTSR1 modulator. SBI-810 hydrochloride promotes the recruitment of β-arrestin-2 to NTSR1 and antagonizes NTSR1-mediated Gq activation. SBI-810 hydrochloride inhibits excitatory synaptic transmission, NMDA receptor and extracellular signal-regulated kinase (ERK) signaling in spinal nociceptive neurons, reduces surface expression of Nav1.7 and action potential firing in primary sensory neurons, and attenuates C-fiber responses. SBI-810 hydrochloride effectively alleviates acute and chronic pain in various rodent models through peripheral and central modulation. SBI-810 hydrochloride is applicable to research related to multiple pain disorders .

HY-164795

SBI-810	Neurotensin Receptor Arrestin iGluR ERK Sodium Channel	Neurological Disease
SBI-810 is a blood-brain barrier-permeable NTSR1 modulator. SBI-810 promotes the recruitment of β-arrestin-2 to NTSR1 and antagonizes NTSR1-mediated Gq activation. SBI-810 inhibits excitatory synaptic transmission, NMDA receptor and extracellular signal-regulated kinase (ERK) signaling in spinal nociceptive neurons, reduces surface expression of Nav1.7 and action potential firing in primary sensory neurons, and attenuates C-fiber responses. SBI-810 effectively alleviates acute and chronic pain in various rodent models through peripheral and central modulation. SBI-810 is applicable to research related to multiple pain disorders .

HY-P990071

Fepixnebart LY-3016859	EGFR	Neurological Disease Metabolic Disease Inflammation/Immunology
Fepixnebart (LY3016859) is a humanized monoclonal hIgG4 antibody, which binds and neutralizes only TGFα and epiregulin with high affinity. Fepixnebart can be used for the study of diabetic nephropathy and broad-spectrum chronic pain, including diabetic peripheral neuropathic pain (DPNP), signs and symptoms of osteoarthritis (OA), and chronic low back pain (CLBP) .

HY-19876

PL37 Debio-0827	Opioid Receptor Aminopeptidase Neprilysin	Neurological Disease Metabolic Disease
PL37 (Debio-0827) is an orally active Enkephalinase dual inhibitor (dual inhibition refers to the simultaneous inhibition of Neutral Endopeptidase and Aminopeptidase N activities). PL37 exerts its anti-hyperalgesic effects by activating μ-opioid receptors (µ-opioid receptors), with an ED₅₀ value of 13.4 mg/kg for analgesic effects in mice. PL37 can be used to study diabetic neuropathic pain .

HY-116005

A-286501	Adenosine Kinase	Neurological Disease Inflammation/Immunology
A-286501 is an orally active and potent carbocyclic nucleoside adenosine kinase inhibitor with an IC₅₀ value of 0.47 nM, which shows analgesic and anti-inflammatory effects. A-286501 reduces nociception in animal models of acute (thermal), inflammatory (formalin and carrageenan) and neuropathic (L5/L6 nerve ligation and streptozotocin-induced diabetic) pain. A-286501 also reduces Carrageenan (HY-125474)-induced paw edema and myeloperoxidase activity in the injured paw. A-286501 is promising for research of analgesic and anti-inflammatory agents .

HY-B0161E

(±)-Duloxetine hydrochloride (Rac)-Duloxetine hydrochloride	Serotonin Transporter	Neurological Disease
(±)-Duloxetine ((Rac)-Duloxetine) hydrochloride is the racemate of Duloxetine hydrochloride. Duloxetine hydrochloride, a serotonin-norepinephrine reuptake inhibitor, can be used for diabetic neuropathic pain and fibromyalgia as well as major depressive disorder research .

HY-14897

Rezatomidine AGN-203818	Adrenergic Receptor	Neurological Disease Metabolic Disease
Rezatomidine (AGN-203818) is a potent and selective α2-AR agonist. Rezatomidine can be used for diabetic neuropathy and neuropathic pain research .

HY-161682

GPR84 antagonist 9	GPR84	Neurological Disease
GPR84 antagonist 9 (compound 320) is an orally active GPR84 antagonist with the IC₅₀ of 0.012 μM. GPR84 antagonist 9 can be used for study of inflammatory-driven pain diseases .

HY-Y0790R

Cuminaldehyde (Standard) p-Isopropylbenzaldehyde (Standard)	α-synuclein Reference Standards	Infection Neurological Disease Inflammation/Immunology Cancer
Cuminaldehyde Standard is the analytical standard of Cuminaldehyde. This product is intended for research and analytical applications. Cuminaldehyde is the main component of Cuminum cyminum and has multiple biological activities, including anti-inflammatory, anti-cancer, anti-diabetic, anti-injury, anti-neuropathy and antibacterial effects. Cuminaldehyde is an inhibitor of aldose reductase (IC₅₀= 0.00085 mg/mL) and α-glucosidase (IC₅₀=0.5 mg/mL). Cuminaldehyde also inhibits the fibrillation of α-synuclein and prevents its aggregation Cuminaldehyde can induce apoptosis in colon adenocarcinoma cells by targeting topoisomerase I and II. In addition, Cuminaldehyde also exerts anti-inflammatory activity by inhibiting lipoxygenase. Cuminaldehyde has a strong inhibitory effect on the growth of Aspergillus flavus and the biosynthesis of aflatoxin B1 (AFB1). Cuminaldehyde can exert anti-injury and anti-neuropathy effects by participating in opioid receptors, L-arginine/NO/cGMP pathways and anti-inflammatory effects. Cuminaldehyde has potential application value in the research of neurodegenerative diseases, cancer, diabetes and neuropathic pain diseases .

HY-B0161ES

(±)-Duloxetine-d3 hydrochloride (Rac)-Duloxetine-d3 hydrochloride	Isotope-Labeled Compounds Serotonin Transporter	Neurological Disease
(±)-Duloxetine-d₃ (hydrochloride) is deuterium labeled (±)-Duloxetine (hydrochloride). (±)-Duloxetine ((Rac)-Duloxetine) hydrochloride is the racemate of Duloxetine hydrochloride. Duloxetine hydrochloride, a serotonin-norepinephrine reuptake inhibitor, can be used for diabetic neuropathic pain and fibromyalgia as well as major depressive disorder research .

HY-145487A

5-Hydroxy-6-methoxy (S)-duloxetine maleate	5-HT Receptor Adrenergic Receptor	Neurological Disease
5-Hydroxy-6-methoxy (S)-duloxetine maleate is an orally active and brain-penetrant serotonin (5-HT) and norepinephrine (NE) reuptake inhibitor with antidepressant and analgesic activities. 5-Hydroxy-6-methoxy (S)-duloxetine maleate is promising for research of psychiatric and neurological disorders such as depression, diabetic neuropathic pain, generalized anxiety disorder, and fibromyalgia .

HY-168214

Kv7.2/Kv7.3 agonist 1	Potassium Channel	Neurological Disease
Kv7.2/Kv7.3 agonist 1 (Compound 16) is an orally active agonist for KV7.2/7.3 channel (KCNQ2/3) with an EC₅₀ of 1.03 μM. Kv7.2/Kv7.3 agonist 1 exhibits analgesic efficacy in mice chronic constriction injury (CCI) model and mice Streptozotocin (HY-13753)-induced diabetic peripheral neuropathic pain (DPNP) model, with ED₅₀ of 12.02 and 9.63 mg/kg .

HY-146281

mGAT3/4-IN-2	GABA Receptor	Neurological Disease Metabolic Disease
mGAT3/4-IN-2 (compound 27b) is a potent mGAT3/mGAT4 inhibitor, with pIC₅₀ values of 5.44 and 5.25, respectively .

HY-146280

mGAT3/4-IN-1	GABA Receptor	Neurological Disease Metabolic Disease
mGAT3/4-IN-1 (compound 19b) is a potent mGAT3/mGAT4 inhibitor, with pIC₅₀ values of 5.31 and 5.24, respectively. mGAT3/4-IN-1 exhibits a significant tactile allodynia reduction in diabetic neuropathic mice .

HY-182539

DD04107	CGRP Receptor	Others Neurological Disease
DD04107 is a neuronal exocytosis inhibitor with a rat Syt1-C2B domain binding K_a of 2.4 μM. DD04107 interferes with synaptobrevin-syntaxin-SNAP-25 complex formation and Syt1-SNARE complex interaction to block α-calcitonin gene-related peptide (α-CGRP) exocytotic release from primary sensory neurons. DD04107 blocks inflammatory ion channel recruitment to nociceptor plasma membranes. DD04107 can be used for the research of chronic inflammatory pain, neuropathic pain, osteosarcoma pain, chemotherapy-induced peripheral neuropathy, diabetic neuropathy, inflammatory pain .

Art. -Nr.	Produktname	Target	Research Area